Article Text

Download PDFPDF

#263 Real world experience with PARPi maintenance use in ovarian cancer
  1. Natalia Dolores Pérez Rodríguez,
  2. Ana Isabel Martín Quesada,
  3. Mónica Vilar Chesa,
  4. Maximina Suarez Díaz,
  5. María López Acosta,
  6. Lina A Pérez Mendez and
  7. Alfonso Quesada López
  1. University Hospital Nuestra Señora de Candelaria, Santa Cruz De Tenerife, Spain


Introduction/Background Survival of ovarian carcinoma has improved in recent years due to determination of the homologous recombination deficit (HRD), and the use of first-line maintenance with PARP inhibitors (PARPi).

The aim of our study was to do a real world study in patients treated in our Center.

Methodology A cross-sectional longitudinal observational study was designed in a cohort of 100 patients diagnosed with ovarian cancer during the period 2018 to 2022. HRD was determined by Myriad myChoice test. The variables to be studied were: somatic mutation, and germline if positive by NGS, type of mutation, age at diagnosis, histology, stage, primary or interval surgery after neoadjuvant chemotherapy, response, PARPi, progression free survival (PFS), and allergy to chemotherapy.

Results The mean age at diagnosis of ovarian carcinoma was 62 years, with a predominance of 50% stage IIIC, and 80% of serous histology grade 3. 32% were HRD positive, with BRCA1 in 55%, BRCA2 in 10%, and the remaining 35% others of the RAD51C, BRIP1.

68% of cases received neoadjuvant chemotherapy, and only 50% were candidates for interval surgery. Primary surgery was performed in 32% of patients. Results: CR 38.4%, PR 53.5%. SD: 2% and progression 6.1%. Allergic reaction to chemotherapy occurred in 22% of the total.

38% of patients received PARPi as first-line maintenance.

In the group of patients who progressed to first line (49% of our series), PFS was higher in those with somatic line pathogenic variants, presenting a median of 18 months versus 10 months, (p=0.015).

Conclusion The results of our case series are compatible with those published in the literature, highlighting the increase in PFS in HRD+ patients who have received maintenance with PARPi. We found an increase of allergic reactions in patients carrying pathogenic germline variants, probably due to splicing-related mechanisms. These data should be cross-checked with other future studies.

Abstract #263 Figure 1

Stage/Progression. PFS/HRD

Disclosures No

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.